This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Polycystic Ovary Syndrome Genetics and Treatment Response

This study is ongoing, but not recruiting participants.
American Diabetes Association
Information provided by (Responsible Party):
Corrine Welt, Massachusetts General Hospital Identifier:
First received: July 6, 2011
Last updated: March 21, 2017
Last verified: March 2017
July 6, 2011
March 21, 2017
June 2011
October 2018   (Final data collection date for primary outcome measure)
Insulin Sensitivity [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT01389778 on Archive Site
  • Androgen Levels [ Time Frame: 3 months ]
  • Ovulatory Rate [ Time Frame: 3 months ]
Same as current
Not Provided
Not Provided
Polycystic Ovary Syndrome Genetics and Treatment Response
Polycystic Ovary Syndrome Genetics and Treatment Response

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women. Women with PCOS have a high risk of prediabetes, type 2 diabetes and heart disease. The investigators have found a possible change in the DNA (genes of the body that encode all of our traits) that seems to be related to insulin resistance. In this study, the investigators will try to determine whether the change in the gene affects a woman's ability to respond to a common treatment for PCOS, metformin.

These studies will uncover the change in a gene that might be one of the causes of PCOS. Discovering this gene will help better understand the diabetes and insulin abnormalities that are common in PCOS and will help us to better diagnose and treat PCOS to prevent the diabetes in these women.

Polycystic ovary syndrome (PCOS), which affects 7-10% of reproductive aged women, has traditionally been classified as a reproductive and dermatologic syndrome because of its high rate of infertility and the cosmetic complications of hyperandrogenism. However, it has become increasingly clear that insulin resistance is important in the pathogenesis of the disorder.

There are a number of variants that have been determined to be associated with PCOS risk. The investigators will determine the effect of these variants on the phenotype and response to treatment in PCOS. Subjects with PCOS will undergo extensive phenotyping including adipose tissue biopsy, dual energy X-ray absorptiometry (DXA, bone density) scan to examine adipose stores, an intravenous glucose tolerance test to study insulin sensitivity and beta cell function, androgen stimulation and inflammatory markers. The phenotyping will be repeated after 3 months of treatment with metformin. The studies will determine whether the genotype at PCOS risk variants dictates phenotype and response to treatment with metformin. Discovering genes involved in the etiology of PCOS will help pull us out of the endless circle that has characterized our understanding of PCOS pathophysiology for many years. The proposal also has the potential to illuminate one etiology of insulin resistance, which is present even in lean women with PCOS, and the impaired glucose tolerance and diabetes found in over 40% of PCOS patients.

Not Provided
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Polycystic Ovary Syndrome
  • Drug: Metformin ER
    Metformin ER 1500 mg for 12 weeks
  • Drug: Metformin
Experimental: Metformin
Subjects treated with metformin.
  • Drug: Metformin ER
  • Drug: Metformin
Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014 May;99(5):1870-8. doi: 10.1210/jc.2013-4021. Epub 2014 Feb 25.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
October 2018
October 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Polycystic ovary syndrome
  • No medications for 1 month
  • Good general health

Exclusion Criteria:

  • Smoker
  • Acute infection or chronic disease
  • Diabetes
  • Trying to get pregnant
  • Bleeding disorders
Sexes Eligible for Study: Female
18 Years to 40 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Corrine Welt, Massachusetts General Hospital
Massachusetts General Hospital
American Diabetes Association
Not Provided
Massachusetts General Hospital
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP